Core Viewpoint - The increasing prevalence of "three highs" (high blood pressure, high blood sugar, and high blood lipids) poses a significant public health challenge, with high blood lipids being particularly insidious due to a lack of early symptoms [1][2]. Group 1: Prevalence and Risk Factors - A significant percentage of patients with hypertension (61.5%) also have lipid abnormalities, while 65.8% of those with lipid abnormalities have hypertension, and 67.1% of diabetes patients have lipid issues [2]. - The overall prevalence of hyperlipidemia among Chinese residents aged 18 and above is 35.6%, indicating that approximately 1 in 3 to 4 adults suffers from this condition [2]. - Genetic factors contribute to over 50% of lipid issues, making individuals with a family history of high blood lipids or cardiovascular diseases more susceptible [2]. Group 2: Management and Detection - The "Chinese Blood Lipid Management Guidelines (2023)" recommend that adults under 40 should have lipid tests every 2 to 5 years, while those 40 and older should be tested at least annually [4]. - It is crucial to interpret lipid test results correctly, focusing on risk levels (low, medium-high, high, extremely high) to set appropriate lipid-lowering targets [4]. - For extremely high-risk patients with established atherosclerotic cardiovascular disease, LDL-C levels should be reduced to below 1.4 mmol/L, with a reduction of more than 50% from baseline [4]. Group 3: Lifestyle Recommendations - To improve lipid management, adopting a healthy lifestyle is essential, including a balanced diet, regular exercise (at least 150 minutes of moderate-intensity activity weekly), and avoiding smoking and excessive alcohol [5]. - If lifestyle changes do not yield results, it is important to follow medical advice for long-term medication adherence [5]. Group 4: Importance of Awareness - Heart and cerebrovascular diseases, often referred to as "cancers among common diseases," can be effectively managed through scientific approaches to the "three highs," particularly high blood lipids, which are often overlooked [6].

证券研究报告 海外MNC动态跟踪系列（八） 默沙东：K药卫冕药王宝座，索特西普表现亮眼 医药 强于大市（维持） 平安证券研究所 医药团队 分析师： 研究助理： 叶寅 投资咨询资格编号:S1060514100001 邮箱：YEYIN757@PINGAN.COM.CN 韩盟盟 投资咨询资格编号:S1060519060002 邮箱：HANMENGMENG005@PINGAN.COM.CN 张梦鸽 一般证券从业资格编号:S1060124120037 邮箱：ZHANGMENGGE752@PINGAN.COM.CN 2025年3月4日 请务必阅读正文后免责条款 行业观点 2025 年，默沙东重点数据读出如下： 2 事件：2月4日，默沙东公布2024年业绩，总营收641.68亿美元，同比增长7%。2024年全年每股收益为7.65美元（按非GAAP计算），2024年研发 支出为179亿美元。从营收情况看，业绩主要由帕博利珠单抗、四价/九价人乳头瘤病毒疫苗和动物保健板块贡献，其中帕博利珠单抗2024年实 现销售额295亿美元，继续蝉联"药王"宝座，HPV疫苗2024年实现收入86亿美元，动物保健板块2024年实现收入59亿美元 ...